<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05101564</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-52869</org_study_id>
    <secondary_id>BRS0124</secondary_id>
    <nct_id>NCT05101564</nct_id>
  </id_info>
  <brief_title>Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer</brief_title>
  <official_title>An Umbrella, Randomized, Controlled, Pre-Operative Trial Testing Integrative Subtype-Targeted Therapeutics in Hormone Receptor-Positive, HER2-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if adding a new drug that is targeted at a specific&#xD;
      genetic change found in some breast tumors pre-operatively will slow the growth of the tumor&#xD;
      more than standard anti-hormone therapy used to treat this type of breast cancer. Different&#xD;
      therapies are being tested based on the specific gene changes in the tumor. Not every tumor&#xD;
      will have a gene change that is being studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To evaluate the efficacy of investigational agent compared with standard&#xD;
      endocrine therapy in in reducing Ki67 values based on digital pathology (QuPath) from&#xD;
      baseline to on-treatment biopsy after an specific treatment duration (i.e. 14 or 18 days) in&#xD;
      ER-positive, HER2-negative tumors (tumor size ≥1 cm) with Ki67 ≥ 10%, for different&#xD;
      integrative subtype categories identified at integrative subtype screening.&#xD;
&#xD;
      Secondary Objective: To evaluate the efficacy of investigational agent compared with standard&#xD;
      endocrine therapy on the proportion of subjects with Ki67 &lt; 10% after a specific treatment&#xD;
      duration (i.e. 14 or 18 days)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in Ki67</measure>
    <time_frame>Measured pre-treatment and after treatment 15 or 19 days, based on the duration specified for the assigned therapy</time_frame>
    <description>The primary outcome for this study is the change in digital pathology software-assessed quantitative Ki67 IHC from pre-treatment specimen to the on-treatment specimen. For analysis purposes, the change in Ki67 will be assessed on log-transformed values. The outcome will be expressed as mean and standard deviation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ki67 &lt;10% on-treatment measurement</measure>
    <time_frame>15 or 19 days, based on the duration specified for the assigned therapy</time_frame>
    <description>The proportions of subjects with Ki67 less than 10% after treatment. The outcome will be reported as a number without dispersion.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <condition>ER Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IC1:Alpelisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrative subtype IC1, Treatment (14 days, - 2 or + 7 days): Take assigned alpelisib pills, 300 mg (two 150 mg tablets) with food, once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC1:Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Integrative subtype 1, Treatment (14 days, -2 to +7 days): Take assigned tamoxifen pills, 20 mg once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC2:Infigratinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrative subtype 2, Treatment (18 days, - 2 to +3 days): Take assigned infigratinib pills, 100 mg once daily by mouth in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC2:Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Integrative subtype 2, Treatment (18 days, - 2 to +3 days): Take assigned tamoxifen pills, 30 mg once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC6:Infigratinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Integrative subtype 2, Treatment (18 days, - 2 to +3 days): Take assigned tamoxifen pills, 30 mg once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC6:Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Integrative subtype 6, Treatment (18 days, - 2 to +3 days): Take assigned tamoxifen pills, 30 mg once daily by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC9: Amcenestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrative subtype 9, Amcenestrant 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC9: Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Integrative subtype 9, Letrozole 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Typical risk: Amcenestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrative subtypes 3, 4, 7, 8, Amcenestrant 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Typical risk: Amcenestrant + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Integrative subtypes 3, 4, 7, 8 , Drug: Amcenestrant 200 mg, Drug: Letrozole 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Typical risk: Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Integrative subtypes 3, 4, 7, 8, Drug: Letrozole 2.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpelisib</intervention_name>
    <description>Alpelisib 300 mg</description>
    <arm_group_label>IC1:Alpelisib</arm_group_label>
    <other_name>Piqray</other_name>
    <other_name>BYL719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Tamoxifen 20 mg</description>
    <arm_group_label>IC1:Tamoxifen</arm_group_label>
    <arm_group_label>IC2:Tamoxifen</arm_group_label>
    <arm_group_label>IC6:Tamoxifen</arm_group_label>
    <other_name>Soltamox</other_name>
    <other_name>TAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infigratinib</intervention_name>
    <description>Infigratinib 100 mg</description>
    <arm_group_label>IC2:Infigratinib</arm_group_label>
    <arm_group_label>IC6:Infigratinib</arm_group_label>
    <other_name>Truseltiq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amcenestrant</intervention_name>
    <description>Amcenestrant 200 mg</description>
    <arm_group_label>IC9: Amcenestrant</arm_group_label>
    <arm_group_label>Typical risk: Amcenestrant</arm_group_label>
    <arm_group_label>Typical risk: Amcenestrant + Letrozole</arm_group_label>
    <other_name>SAR439859</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole 2.5 mg</description>
    <arm_group_label>IC9: Letrozole</arm_group_label>
    <arm_group_label>Typical risk: Amcenestrant + Letrozole</arm_group_label>
    <arm_group_label>Typical risk: Letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre-Screening Phase&#xD;
&#xD;
          -  Biopsy-proven ER-positive, HER2-negative breast cancer. ER-positivity and&#xD;
             PR-positivity are defined as ≥1% cells staining positive by immunohistochemistry.&#xD;
             HER2-negativity is defined by IHC or FISH, per ASCO-CAP 2018 guidelines. Breast tumor&#xD;
             must be intact and tumor size must be ≥ 1 cm as measured by ultrasound, mammogram,&#xD;
             MRI, or clinical exam. If tumor is locally recurrent, it must be in the breast (not&#xD;
             skin, node, or chest wall recurrence). Ki67 may or may not have been done locally but&#xD;
             if done locally, must be ≥ 5%. Any nodal status is allowed, as M0 or M1 disease.&#xD;
&#xD;
          -  Women or men, age ≥ 18 years old.&#xD;
&#xD;
          -  Able to swallow and retain oral medication.&#xD;
&#xD;
          -  Performance status 0 to 1 (by Eastern Cooperative Oncology Group [ECOG] scale).&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Treatment Phase&#xD;
&#xD;
          -  Breast tumor classifies as relevant integrative subtype per tumor sequencing performed&#xD;
             and analyzed by central laboratory.&#xD;
&#xD;
          -  Breast tumor Ki67 score ≥ 10% as assessed by central laboratory.&#xD;
&#xD;
          -  Each investigational agent specific inclusion criteria can be found in the&#xD;
             agent-specific appendix&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman, as confirmed by positive serum hCG test prior to initiating study&#xD;
             treatment. Nursing (lactating) woman also not allowed.&#xD;
&#xD;
          -  Prior breast cancer-directed therapy (surgery, radiation, chemotherapy, or endocrine&#xD;
             therapy) is not allowed, with the exception of people with in-breast recurrences.&#xD;
             People with in-breast recurrences cannot have had breast cancer-directed therapy&#xD;
             (radiation, chemotherapy, or endocrine therapy; surgery is acceptable) within the 6&#xD;
             months prior to signing the pre-screening consent. Pre-endocrine therapy for breast&#xD;
             cancer risk reduction is allowed.&#xD;
&#xD;
          -  Known hypersensitivity to study agent (IP) or standard endocrine therapy drug, or to&#xD;
             any of the excipients of study agent (IP) or standard endocrine therapy drug.&#xD;
&#xD;
          -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significant alter the absorption of the study drugs (e.g. ulcerative diseases,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel&#xD;
             resection) based on investigator discretion&#xD;
&#xD;
          -  Each study agent specific exclusion criteria can be found in the agent-specific&#xD;
             appendix&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Sledge</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Universiy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison Zhang</last_name>
    <phone>650-736-5790</phone>
    <email>axkong@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Allison Zhang</last_name>
    </contact>
    <investigator>
      <last_name>George Sledge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Infigratinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

